With deep molecular insights from a simple blood sample, Caris Assure™ offers a minimally-invasive liquid biopsy option for biomarker analysis of cancer patients when tissue samples are not available. No matter the specimen type – tissue or blood – Caris Life Sciences’ flexible, multi-faceted molecular profiling platforms deliver uncompromising reliability and performance to guide personalized treatment decisions and help improve patient outcomes.*
Technology
Circulating Nucleic Acid Sequencing
(cNAS)
Application
Biomarker Analysis (including resistance mutations)
Biological Coverage
Plasma: cfDNA, cfRNA
White Blood Cells: gDNA, mRNA
Variant Coverage (pathogenic and likely pathogenic)
Tumor-Derived Incidental Germline† Incidental CHIP
Genes & Depth
23,000+ 8,000x (raw average for clinically relevant genes)
Next Generation Sequencing
Whole Exome
Whole Transcriptome
Alterations
SNV INDEL CNA Fusions
Genomic Signatures/Other
bTMB HLA Genotype MSI
Sample Quantity
Two Tubes Whole Blood
Performance in Advanced/Metastatic Patients
Compared to matched tissue collected within 30 days; based on ≥5 ng of cNAS input.
Clinically Actionable SNV and INDEL:
Sensitivity 93.8%
Specificity >99%
PPV 96.8%
LOD 0.1% VAF
Incidental Germline† :
Sensitivity >99%
Specificity >99%
PPV >99%
Caris molecular profiling leverages a multi-faceted approach to personalized cancer treatment. By identifying tumor-derived somatic variants, plus incidental germline† and incidental CHIP variants, Caris Assure provides clinicians with the comprehensive molecular intelligence needed to develop treatment plans that may help improve patient outcomes.
Somatic (acquired) variants are genetic alterations that are not present in egg or sperm cells but occur after conception, and therefore cannot be inherited by following generations. Somatic variants are classified by the level of clinical actionability in the Caris Assure report and can be tumor-specific.
Germline (hereditary) variants are genetic alterations that are present in egg or sperm cells. Such variants will be present in every cell of the body when inherited by offspring. Recognizing germline mutations in predisposed individuals can assist in risk reduction and cancer prevention. Caris Assure analyzes genomic DNA from circulating white blood cells and can distinguish incidental germline‡ mutations from somatic mutations.
Clonal hematopoiesis of indeterminate potential (CHIP) mutations are common age-related somatic mutations that accumulate in the cells of blood or bone marrow. CHIP mutations create biological “noise” that may cause false positive results. Caris Assure distinguishes somatic CHIP mutations from somatic tumor mutations to reduce false positives and improve specificity.
Please complete the form below to have a Caris Scientific Rep (Medical Science Liaison) contact you directly.
"*" indicates required fields
*Caris Assure™ is intended for patients with previously diagnosed solid malignant neoplasms when tissue is infeasible and is to be used by qualified healthcare professionals. RNA results are intended for investigational purposes only. Not available in all locations.
† Not a replacement for comprehensive germline testing. Incidental pathogenic alterations detected in ACMG recognized cancer genes are reported. Negative results do not imply the patient does not harbor a germline mutation.
Place an order today for a comprehensive, personalized Caris profiling report.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |